Literature DB >> 28685291

Filovirus Strategies to Escape Antiviral Responses.

Judith Olejnik1, Adam J Hume1, Daisy W Leung2, Gaya K Amarasinghe2, Christopher F Basler3, Elke Mühlberger4.   

Abstract

This chapter describes the various strategies filoviruses use to escape host immune responses with a focus on innate immune and cell death pathways. Since filovirus replication can be efficiently blocked by interferon (IFN), filoviruses have evolved mechanisms to counteract both type I IFN induction and IFN response signaling pathways. Intriguingly, marburg- and ebolaviruses use different strategies to inhibit IFN signaling. This chapter also summarizes what is known about the role of IFN-stimulated genes (ISGs) in filovirus infection. These fall into three categories: those that restrict filovirus replication, those whose activation is inhibited by filoviruses, and those that have no measurable effect on viral replication. In addition to innate immunity, mammalian cells have evolved strategies to counter viral infections, including the induction of cell death and stress response pathways, and we summarize our current knowledge of how filoviruses interact with these pathways. Finally, this chapter delves into the interaction of EBOV with myeloid dendritic cells and macrophages and the associated inflammatory response, which differs dramatically between these cell types when they are infected with EBOV. In summary, we highlight the multifaceted nature of the host-viral interactions during filoviral infections.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28685291      PMCID: PMC5973841          DOI: 10.1007/82_2017_13

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  247 in total

1.  In silico identification, structure prediction and phylogenetic analysis of the 2'-O-ribose (cap 1) methyltransferase domain in the large structural protein of ssRNA negative-strand viruses.

Authors:  Janusz M Bujnicki; Leszek Rychlewski
Journal:  Protein Eng       Date:  2002-02

Review 2.  The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity.

Authors:  Ian M Copple; Christopher E Goldring; Neil R Kitteringham; B Kevin Park
Journal:  Toxicology       Date:  2007-11-12       Impact factor: 4.221

Review 3.  Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response.

Authors:  John Hiscott
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-13       Impact factor: 7.638

4.  Suppression of Fas-mediated apoptosis via steric shielding by filovirus glycoproteins.

Authors:  Osamu Noyori; Eri Nakayama; Junki Maruyama; Reiko Yoshida; Ayato Takada
Journal:  Biochem Biophys Res Commun       Date:  2013-11-12       Impact factor: 3.575

Review 5.  RNAi and retroviruses: are they in RISC?

Authors:  Thierry Vasselon; Manuella Bouttier; Anne Saumet; Charles-Henri Lecellier
Journal:  Biomol Concepts       Date:  2013-02

6.  Inhibition of filovirus replication by the zinc finger antiviral protein.

Authors:  Stefanie Müller; Peggy Möller; Matthew J Bick; Stephanie Wurr; Stephan Becker; Stephan Günther; Beate M Kümmerer
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

7.  Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis.

Authors:  E Ryabchikova; L Kolesnikova; M Smolina; V Tkachev; L Pereboeva; S Baranova; A Grazhdantseva; Y Rassadkin
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

9.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

10.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

View more
  9 in total

1.  A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.

Authors:  Courtney Woolsey; Andrea R Menicucci; Robert W Cross; Priya Luthra; Krystle N Agans; Viktoriya Borisevich; Joan B Geisbert; Chad E Mire; Karla A Fenton; Allen Jankeel; Sneha Anand; Hideki Ebihara; Thomas W Geisbert; Ilhem Messaoudi; Christopher F Basler
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

Review 2.  Current status of small molecule drug development for Ebola virus and other filoviruses.

Authors:  Megan R Edwards; Christopher F Basler
Journal:  Curr Opin Virol       Date:  2019-04-16       Impact factor: 7.090

3.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 4.  Immune barriers of Ebola virus infection.

Authors:  Anita K McElroy; Elke Mühlberger; César Muñoz-Fontela
Journal:  Curr Opin Virol       Date:  2018-02-16       Impact factor: 7.090

5.  Marburg Virus Viral Protein 35 Inhibits Protein Kinase R Activation in a Cell Type-Specific Manner.

Authors:  Adam Hume; Elke Mühlberger
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 6.  Distinct Genome Replication and Transcription Strategies within the Growing Filovirus Family.

Authors:  Adam J Hume; Elke Mühlberger
Journal:  J Mol Biol       Date:  2019-06-29       Impact factor: 5.469

Review 7.  Recent advances in marburgvirus research.

Authors:  Judith Olejnik; Elke Mühlberger; Adam J Hume
Journal:  F1000Res       Date:  2019-05-21

Review 8.  Factors affecting RIG-I-Like receptors activation - New research direction for viral hemorrhagic fevers.

Authors:  Paulina Małkowska; Paulina Niedźwiedzka-Rystwej
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

9.  Egyptian Rousette IFN-ω Subtypes Elicit Distinct Antiviral Effects and Transcriptional Responses in Conspecific Cells.

Authors:  Stephanie S Pavlovich; Tamarand Darling; Adam J Hume; Robert A Davey; Feng Feng; Elke Mühlberger; Thomas B Kepler
Journal:  Front Immunol       Date:  2020-03-13       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.